Update on long-term outcomes for chronic rhinosinusitis in cystic fibrosis

Update on long-term outcomes for chronic rhinosinusitis in cystic fibrosis: Purpose of review

This article reviews the existing body of literature regarding long-term outcomes of various treatments for chronic rhinosinusitis (CRS) in the cystic fibrosis population.

Recent findings

The management of CRS in cystic fibrosis involves a multitude of medical and surgical therapies. Despite their high usage amongst clinicians, corticosteroids and antibiotics currently have little outcome data supporting their use. There is emerging evidence demonstrating beneficial outcomes for DNAse mucolytics and molecular modulators of cystic fibrosis transmembrane conductor regulator (CFTR). Endoscopic sinus surgery (ESS) improves sinonasal outcomes in cystic fibrosis CRS; however, the benefit on pulmonary outcomes remains unclear.

Summary

Successful management of CRS in cystic fibrosis requires multimodal and multidisciplinary care. The long-term outcome data is variable for different treatment modalities. There is recent evidence supporting the role of DNAse mucolytics, CFTR-targeting therapies, and ESS in management of cystic fibrosis CRS.

Correspondence to Zara M. Patel, MD, Stanford University School of Medicine, Department of Otolaryngology – Head and Neck Surgery, 801 Welch Rd., Stanford, CA 94305, USA. Tel.: +1 650 725 6500;. fax: +1 650 725 8502; e-mail: zmpatel@stanford.edu

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.